COVID-19 vaccines were developed with an unprecedented pace since the beginning of the
pandemic. Several of them have reached market authorization and mass production …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

The emergence of SARS-CoV-2 variants is jeopardizing the effectiveness of current
vaccines and limiting the application of monoclonal antibody-based therapy for COVID-19 …

To investigate the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in the immune population, we coincupi bated the authentic virus with a highly neutralizing …

The global emergency caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic can only be solved with effective and widespread preventive and …

Background and objective Few head‐to‐head evaluations of immune responses to different
vaccines have been reported. Methods Surrogate virus neutralization test (sVNT) antibody …

Multiple SARS-CoV-2 variants have mutations in the spike receptor binding domain (RBD)
with potential to evade neutralizing antibody. In particular, the Beta and Omicron variants …

Antibody titers against SARS-CoV-2 slowly wane over time. Here, we examined how time
affects antibody potency. To assess the impact of antibody maturation on durable …